Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T89 for Improving Oxygen Saturation and Clinical Symptoms in COVID-19
NCT04285190Withdrawn
- Sponsor
- Tasly Group
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of Compound Danshen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tasly Group. Primary endpoints: The time to oxygen saturation recovery to normal level (≥97%), The proportion of patients with normal level of oxygen saturation (≥97%) and 1 more. Planned start Feb 2020; status: withdrawn.
02
Drugs
Compound Danshen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04285190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285190.